Retatrutide

Triple agonist (GLP-1, GIP, and glucagon receptors)
that improves insulin sensitivity, appetite
suppression, and fat oxidation.

Faster injury recovery, reduced inflammation, gut
healing, protection from NSAID damage.

Available in: Self-Injections

Member Price:

$199.00

Non - Member Price:

$299.00

Product:

Retatrutide

Dose:

30mg

One-Time Purchase:

$599.00

Price:

$299.00
Save 33% instantly as a Member — Join now
Anti-Aging

Anti-aging

brain (2)

Clear brain fog

Energy_Boost

Improve mental clarity

Recovery

Support recovery

Retatrutide-2-newhope-wellness-advisors

What is Retatrutide?

Retatrutide is a next-generation metabolic peptide developed by Eli Lilly, designed to target three key metabolic receptors at once — GLP-1, GIP, and glucagon.
This unique triple-agonist action helps regulate appetite, improve insulin sensitivity, enhance fat metabolism, and promote powerful weight reduction.

In simple terms, Retatrutide helps the body burn fat more efficiently, control cravings, and stabilize blood sugar — offering stronger, faster, and longer-lasting results than single-pathway peptides like Semaglutide or Tirzepatide.

Benefits of Retatrutide

Retatrutide-3-newhope-wellness-advisors

Ordering is Easy and Convenient

Choose Your Product

Browse our selection of products and select the one that best suits your needs.

Place Your Order

Finalize your purchase in just a few clicks. Enjoy a smooth and reliable ordering experience every time.

Receive Shipment

Sit back and relax while we deliver your package securely. Fast, reliable shipping ensures you receive your items hassle-free.

Real medications. Real
providers. Real results

Frequently
asked
questions

How does Retatrutide differ from Semaglutide or Tirzepatide?

Retatrutide is a triple-receptor agonist (GLP-1, GIP, and glucagon), whereas Semaglutide activates only GLP-1 and Tirzepatide activates GLP-1 + GIP.
This makes Retatrutide more comprehensive in targeting appetite, energy use, and fat metabolism.

It’s typically given as a once-weekly subcutaneous injection.

Clinical studies show an average of 20–25% body-weight reduction over 48 weeks, depending on dosage and lifestyle.

The most common are mild nausea, digestive discomfort, or reduced appetite — which usually fade as the body adjusts.

As of 2025, it’s still undergoing clinical trials but is widely recognized as the next breakthrough in metabolic therapy.

Your shipment should arrive within one week after placing the order online.

BPC-157 Injections should be kept refrigerated after reconstitution.

This product is not covered by insurance.